Experimental drug targets dangerous calcium spike in cancer
NCT ID NCT04198480
First seen Sep 18, 2026 · Last updated Sep 18, 2026
Summary
Researchers are testing an experimental drug called JMT103 in adults with cancer whose blood calcium levels are dangerously high and who have not responded to standard intravenous bisphosphonate treatment. Participants receive JMT103 as an injection under the skin every four weeks, with extra loading doses in the first two weeks. The trial measures whether the drug can bring corrected serum calcium down to a safer level within 10 days of the first dose. This is a small, early-phase study designed to assess both safety and potential benefit.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- JMT103, an experimental injectable drug
- What this could lead to
- If it works, JMT103 could offer a new option for cancer patients whose high blood calcium no longer responds to standard intravenous bisphosphonates.
- What could go wrong
- This is a very small, early-stage trial with only a handful of participants, so results may not hold up in larger studies. JMT103 is experimental, and its safety and effectiveness in this setting are not yet established.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 1/2
Runs two stages together: safety and dose first, then whether the treatment works.
- Participants
-
4 people
The number who actually took part.
- Started
-
Apr 2020
- Finished
-
Oct 2021
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. Fully informed and signed informed consent. 2. Male or female, Adults (\>/=18 years). 3. Hypercalcemia of Malignancy (HCM) as defined as documented histologically or cytologically confirmed cancer and a corrected serum calcium (CSC) \> 12.5 mg/dL (3.1 mmol /L). 4. Last IV bisphosphonate treatment must be \>/= 7 days and \</= 30 days before the screening corrected serum calcium; or Last hydration therapy must be \>/= 24 hours before the screening corrected serum calcium（Incompatible bisphosphonate）. 5. Adequate organ function. Exclusion Criteria: 1. Pregnancy. 2. Hyperparathyroidism, or other granulomatous disease. 3. Hepatitis b surface antigen positive. 4. Hepatitis c antibody positive, or HIV antibody positive. 5. Receiving dialysis for renal failure. 6. Known sensitivity to JMT103 composition. 7. Treatment with thiazides, calcitonin, mithramycin, or gallium nitrate within their window of expected therapeutic effect (as determined by the physician) prior to the date of screening CSC. 8. Treatment with cinacalcet within 4 weeks prior to the date of screening CSC. 9. Currently participating another clinical study，or Four weeks or less since receiving an investigational product in another clinical study. 10. In the opinion of the investigator , being unsuitable for inclusion in the study，or subjects withdraw informed consent. 11. Treatment with monoclonal antibody to RANK ligand (RANKL) within 180 days prior to the date of the screening CSC.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Hypercalcemia of malignancy are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Shanghai East Hospital
Shanghai, 200123, China